AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02599831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical pudendal nerve stimulation
Description: Four sacrococcygeal points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the root of the penis (perineum) or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the root of the penis (perineum). After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
Study NCT02599831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFM training
Description: A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
Study NCT02599831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal ES
Description: A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
Study NCT01847014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan tablet, dose of 10 mg, once daily.
Study NCT01813110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 g prescription omega-3 concentrate
Description: 4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
Study NCT01813110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: olive oil
Study NCT04087213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemoCare™ Hemodialysis System
Description: The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
Study NCT02671409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neural Mobilization (exercise)
Description: Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
Study NCT02671409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilization (exercise)
Description: Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
Study NCT02380027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: This will be a multi-parametric MRI of the prostate
Study NCT02380027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy
Description: This will be a biopsy targeted to suspicious areas on the MRI
Study NCT02380027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRUS-biopsy
Description: This will be a standard 12 core trans-rectal prostate biopsy
Study NCT02413372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Study NCT02413372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02081131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: pancreatic head resection by open method
Study NCT02081131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Description: laparoscopic pancreatoduodenectomy
Study NCT03824418 — intervention group
Intervention type: PROCEDURE
Intervention: Surveillance colonoscopy with chromoendoscopy
Description: Surveillance colonoscopy with chromoendoscopy
Study NCT04040270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live drama+DVD+Worksheets
Description: Interactive live drama was proposed to enhance memories of the audience of health promotion programmes.~The interactive live drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents.
Study NCT04040270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD+Worksheets
Description: The DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents.
Study NCT01722773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipap (Respironics, Inc)
Description: Bipap every night pressure at 15/5 with heated humidifier
Study NCT03274232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUNEKOS ® 200
Description: micro-injections of the study product were performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of female volunteers aged 45-65 years, with photoaging of mild/moderate grade
Study NCT01914731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via frozen capsule
Study NCT03334110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A method of operation: LIMA-GSV-SCVBG
Description: On the experimental group,We treat patients with the operation of LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein
Study NCT03334110 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: BIMA-SCVBG
Description: On the other group, We treat patients with the operation of bilateral internal mammary artery composited LIMA-Right Mammary Artery（RIMA） y graft and anastomose the Right Mammary Artery(RIMA) with selective coronary vein.
Study NCT00807131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient follow-up
Description: Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences. Its objectives are to improve the patient quality of life.
Study NCT00807131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.
Study NCT00807131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug dispensing
Description: The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.
Study NCT00807131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pharmacy usual care
Description: The patient receives no information about their medicines in the pharmacy, unless he asks for it.
Study NCT00605189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Powered Suction Pump (VAC Freedom)
Description: continuous foam based negative pressure wound therapy
Study NCT00605189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Powered Suction Pump
Description: continuous gauze based negative pressure wound therapy
Study NCT00605189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MWT
Description: moist wound therapy
Study NCT03968406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03968406 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03412708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation supported with Virtual Reality
Description: Patients will perform the supervised vestibular exercises in virtual reality environment using a virtual reality goggle (Samsung Gear VR SM323) and a smartphone (Samsung Galaxy S7). The virtual environments consist of 2 media provided by the videos taken with a 360 camera (Samsung Gear 360). 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full.
Study NCT03968406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study NCT03412708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation supported with Virtual Reality
Description: Patients will perform the supervised vestibular exercises in virtual reality environment using a virtual reality goggle (Samsung Gear VR SM323) and a smartphone (Samsung Galaxy S7). The virtual environments consist of 2 media provided by the videos taken with a 360 camera (Samsung Gear 360). 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full.
Study NCT00657449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8
Study NCT00657449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rofecoxib
Description: rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
Study NCT00617851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lot A of Influenza virus vaccine
Description: 1 injection of the trivalent subunit influenza virus vaccine (lot A) administered intramuscularly
Study NCT03834844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Guided Meditation for 10-15 minutes daily for 6 days/week for 6 weeks
Study NCT00617851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lot B of Influenza virus vaccine
Description: 1 injection of the trivalent subunit influenza virus vaccine (lot B) administered intramuscularly
Study NCT00617851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lot C of Influenza virus vaccine
Description: 1 injection of the trivalent subunit influenza virus vaccine (lot C) administered intramuscularly
Study NCT00617851 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator influenza virus vaccine
Description: 1 injection of the trivalent subunit influenza virus vaccine administered intramuscularly
Study NCT00617851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: All 3 consecutive lots of influenza virus vaccine pooled
Description: 1 injection of the pooled trivalent subunit influenza virus vaccine administered intramuscularly
Study NCT00528827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cardene® I.V.
Description: * 5 mcg/kg/min Cardene I.V.~* 2.5 mcg/kg/min Cardene I.V.~* 0.5 mcg/kg/min Cardene I.V.
Study NCT00528827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardene® I.V.
Description: * 5 mcg/kg/min Cardene I.V.~* 2.5 mcg/kg/min Cardene I.V.~* 0.5 mcg/kg/min Cardene I.V.
Study NCT03834844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AF Education
Description: 6 weekly education modules on topics related to AF
Study NCT03834844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Weekly phone call to discuss patient concerns or questions
Study NCT02861573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: IV Q3W
Study NCT02861573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg
Description: Eight 50-mg capsules PO BID
Study NCT02861573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m^2
Description: IV Q3W
Study NCT02861573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg
Description: One 5-mg tablet PO BID
Study NCT02861573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg
Description: Four 40-mg capsules, four 40-mg tablets, or two 80-mg tablets PO QD
Study NCT02861573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Description: Premedication for Cohort B given PO at 12, 3, and 1 hours prior to docetaxel infusion Q3W
Study NCT02861573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg
Description: Two 150-mg tablets PO BID
Study NCT02861573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1000 mg
Description: Two 500-mg or four 250-mg tablets PO QD
Study NCT02861573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg PO QD
Study NCT02861573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab coformulation
Description: IV Q3W
Study NCT02861573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Q3W
Study NCT02861573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV on Days 1, 2 and 3 of each cycle
Study NCT02861573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belzutifan 120mg
Description: PO QD
Study NCT04716803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate Concentrate
Description: Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
Study NCT04716803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angel Concentrated Platelet Rich Plasma (cPRP) System
Description: Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
Study NCT01102361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Transperineal Biopsy
Description: Saturation biopsy for previous negative patients
Study NCT01720719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Oral atorvastatin 20mg, qd, for 24 weeks
Study NCT01720719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Oral Vitamin E 300mg, qd, for 24 weeks
Study NCT04239339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Description: 20mg daily for approximately 3 weeks.
Study NCT04239339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for approximately 3 weeks.
Study NCT00948337 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brochure of Secondary Cancer Screening
Description: One kind of printed educational material
Study NCT00948337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brochure of Secondary Cancer Screening
Description: One kind of printed educational material
Study NCT01561924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptacog alfa (activated)
Description: Subjects will be called to attend the clinic in a non-bleeding state. Blood samples will be drawn for thromboelastogram profiling and will be in-vitro spiked with different doses of activatated recombinant human factor VII.
Study NCT02285348 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar puncture
Description: Lumbar puncture is done according to general practice
Study NCT02043314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazida
Study NCT03473067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Norms Marketing Campaign
Description: This poster based marketing campaign is designed to correct inaccurate perceptions of norms regarding violence.
Study NCT03473067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capacity Building
Description: Schools will participate in teacher training and parent training.
Study NCT01451320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptokinase
Description: 3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units)
Study NCT01451320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptokinase
Description: 24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
Study NCT01451320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue plasminogen activator
Description: 5-hour infusion of 90 mg t-PA (Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
Study NCT01451320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Plasminogen Activator
Description: 6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
Study NCT01451320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Plasminogen Activator
Description: 6-hour infusion of 25 mg t-PA (Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
Study NCT00810706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: Patients randomised to receive exemestane (25 mg/day) for 5 years.
Study NCT05467982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Illness Management and Recovery
Description: Education and skills training groups on illness management of chronic medical and psychiatric illness. Subsample of 75 will also receive COVID-specific Integrated Illness Management and Recovery module.
Study NCT05467982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program
Description: Education and skills training groups on illness management of chronic conditions
Study NCT02310503 — intervention group
Intervention type: PROCEDURE
Intervention: Mohs surgery
Description: A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.
Study NCT01921335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARRY-380 Twice Daily Dosage
Description: ARRY-380 will be administered daily (either twice-daily along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
Study NCT02043314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazida
Study NCT01257503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyland's Cold 'n Cough 4 kids
Description: 5 ml PO q4h prn cold symptoms
Study NCT01921335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARRY-380 Once Daily
Description: ARRY-380 will be administered daily once-daily) along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
Study NCT01921335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 6 mg/kg IV every 3 weeks